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I entered the Rega Institute for Medical Research in August
1964, as a medical student, to start working under the
guidance of Prof. Piet De Somer, then professor of microbiol-
ogy at the Leuven School of Medicine. When I graduated as
medical doctor (MD) in 1966, I hesitated between a clinical
career in Internal Medicine or a scientiﬁc career in experi-
mental research, the latter under the tutorship of Prof. De
Somer who persuaded me to work on interferon (inducers). The
discovery of the interferon-inducing capacity of double-
stranded RNAs, such as poly(I)  poly(C), by Maurice Hille-
man's group at Merck in 1967 would prove of key importance
in my decision to engage in interferon research. In 1968 I
described the induction of interferon by polyacrylic acid and
polymethylacrylic acid; one year after Thomas C. Merigan at
Stanford University had described interferon induction by
pyran copolymer. As a postdoctoral fellow at Stanford (from
1968 till 1970), I discovered, with T.C. Merigan, several new
polynucleotides as inducers of interferon. Upon my return to
Leuven at the end of 1970, I picked up a new line of research,
that of the reverse transcriptase (RT), which had just been16/j.apsb.2015.09.001
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esponsibility of Institute of Materia Medica, Chinese Acdiscovered by Temin (and Mizutani) and Baltimore. In 1975 I
then discovered suramin as a potent RT inhibitor (published in
1979), and this prompted Mitsuya and his colleagues (includ-
ing R.C. Gallo and S. Broder) to evaluate suramin as a
potential anti-HIV agent.
2014 (August 2014 to be precise) marks the 50th anniversary of
my arrival, in 1964, as a 23-year old medical student who had just
passed his 5th year medical studies (second doctorate), at the Rega
Institute. I do not recall it as “une entrée joyeuse” (“blijde intrede”),
but only as a “let us try and see”. That my stay at the Rega would
ﬁnally last for 50 years could hardly be anticipated, at the beginning
of an uneventful start of what later could be considered as an
equally uneventful career. At the age of 18, right on time, I ﬁnished
high school (“Oude” Grieks-Latijnse Humaniora) at the Heilige
Maagd College (HEMACO) in Dendermonde. As Primus Perpe-
tuus, being the ﬁrst of my class from the age of 12 till 18th (Fig. 1),
I was predestined to become a priest, certainly after having studied
the classical humanities (Greco-Latin), but I did not feel like being
summoned by any providence or superior force. Instead, I thought
of mathematics, physics, chemistry or chemical engineering, algebra
being my favored course at high school, but to further enroll at theMedica, Chinese Academy of Medical Sciences. Production and hosting by
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
ademy of Medical Sciences and Chinese Pharmaceutical Association.
Figure 1 Photograph of class Retorica, 1958.
An Odyssey in antiviral drug development 521university in engineering, I would have to follow a preparative year,
which for medicine was not necessary, and my mother dreamed of
seeing her only son becoming a medical doctor in general practice.
She won! Mainly because the heavy emphasis on chemistry in the
ﬁrst undergraduate year of the medical school. And there I went!
The ﬁrst year at the university was partially successful. I passed the
ﬁrst year with “distinction”, the second year, I got “great distinc-
tion”, and the third year, as the only of my class, I climbed up to
“greatest distinction”, by surprise, I should admit, as I did not feel I
deserved such accolade which I rather saw as a discrimination.
Meanwhile, I had started to work in the laboratory as a “free”
student. This was expected only from the best students, and advised
by Prof. Xavier Aubert, professor in physiology (at the future UCL)
and son-in-law of Prof. Albert Dalcq (Université Libre de Bruxelles,
ULB), also permanent secretary of the Royal Academy of Medicine.
I was parachuted in the laboratory of a certain Prof. Raymond
Devis (Laboratoire de Chimie Hormonologique). I missed the
opportunity to start working in the laboratory of Christian de Duve
(who in 1974 would be honored by the Nobel Prize in medicine
or physiology, but this was not obvious (yet) around 1960,
although de Duve's basic discovery of the lysosomes is going back
till 1955). I spent a lot of time in Prof. Devis' laboratory, trying to
set up an analytical test for catecholamines through some spectro-
photometric techniques, but this work carried out in the period
of 1960 till 1963, despite encouragements and ﬂattering comments
of the professor concerned, never resulted in any publication.
Adding to the disenchantment was that I worked in a French
speaking laboratory, which in the wake of the imminent separation
of the university in a Flemish and French speaking section,
gradually became an untenable situation for Flemish-speaking
students of the then called Université Catholique de Louvain
(UCL). The fact that I spent my time in a French-speaking
laboratory was only a small part of the problem, the major part
being it was not an inspiring environment for any signiﬁcant
accomplishment or prospect thereof.
In 1963, at the exam of microbiology (bacteriology), Prof. Piet
De Somer, who must have been informed of the fact that I was not
tremendously enthralled by my “séjour” in Prof. Devis' laboratory,
offered me the opportunity to come to work with him at the Rega
Institute, on viruses. My ﬁrst reaction was “No, thank you. I do notwant to work on viruses, just chemistry”. When my fellow
students and in particular, the preses of the medical students, Olav
Leuridan, heard that I had declined an offer of Prof. De Somer,
who at that time was already Scientiﬁc Adviser to the Rector
Magniﬁcus of the university (Monseigneur Descamps), he told me
I had to be stupid to refuse such an offer. In 1964, again at the
exam of microbiology (virology), Prof. De Somer asked me once
more whether I had in the meantime changed my mind, and I
gladly told him “I had” and that I would start working in his
laboratory on “the chemistry related to viruses”, whatever that
meant. For De Somer, it meant “interferon”. The discovery of
interferon by Isaacs and Lindenmann in 1957, had made De Somer
very enthusiastic about the prospects of interferon as a broad-
spectrum antiviral agent, and he wanted to transmit this enthu-
siasm to myself. At the time, interferon was still an esoteric
principle rather than a molecule, and many chemists I talked to
even doubted that this molecule really existed, but De Somer
believed in it (in 1976 he would lose his belief in “interferon”),
and he could persuade me to start working in his laboratory,
originally not on interferon, but on rubella, in setting up an
immunoﬂuorescent technique to detect antibodies against rubella
virus, and following up on the production of these antibodies in
rabbits given the rubella virus vaccine (this was the Cendehill
strain vaccine that was later commercialized by RIT, and, is as of
today, still part of the GSK vaccines against measles, mumps and
rubella). This work gave rise to sort of a master's thesis which I
must have completed in 1965. For Prof. De Somer, it was
sufﬁcient to drag me into research and start a scientiﬁc career.
In July 1966 (Fig. 2), I ﬁnished my MD studies, graduating as ﬁrst
of the class with the greatest distinction, and Prof. De Somer was
there at my graduation, to tell me he had been of some help in
securing that I got the greatest honor (“maxima cum laude”). It
was not in vain: being confronted with the option of starting a
career in internal medicine (with Prof. Jozuë Vandenbroucke) and
a career in science (with Prof. Piet De Somer), I ﬁrst settled for a
50%–50% solution, which later on became 100% De Somer, and
so in August 1966 I started to work, now full time, in the
laboratory of Prof. De Somer. While in 1964, Prof. De Somer had
tried to couple me to an older colleague Prof. Alfons Billiau, I had
told him by December 1964 that I wanted to work independently,
Figure 2 Photograph of MD graduation, 1966.
Erik De Clercq522and so, by 1966, when I deﬁnitely started to work under Prof. De
Somer's mentorship, he assured me that I would gain full
independence under his ﬁnal guidance, of course.
When I started to work as an MD in Prof. De Somer's
laboratory in August 1966, I was reasonably lucky in that I had
the whole laboratory for myself, about 8 technicians [since at that
time my colleague Dr. Billiau spent a post doc with Sam Baron at
National Institutes of Health (NIH)], whom I had to supervise. I
remember Anick Focant, Josette Costermans, Francine Cornette,
Lieve Aelvoet, and a few others of which I have forgotten the
names by now. This was a luxury I would never have again. Also
Prof. Desmyter, who actually did not belong to the inner circle of
Prof. De Somer, was at this time at Baylor University in Houston. I
made, during August 1966, some observations which Prof. De
Somer found rather exciting: (i) the fact that interferon upon being
induced by Sindbis virus in rabbits, appeared into the urine1,
proving that interferon had a molecular weight sufﬁciently low
(r20,000) to pass the kidney threshold (Prof. De Somer would
present these data at a meeting of the Pan American Health
Organization (PAHO) in Fort Lauderdale), (ii) the fact that
interferon could be induced by synthetic polyanions such as
polyacrylic acid2,3. At about the same time, Tom Merigan at
Stanford University had shown that interferon could also be
induced by synthetic polyanions such as pyran copolymer. Prof.
De Somer met with Dr. Tom Merigan in Fort Lauderdale and
when Prof. De Somer came back from Fort Lauderdale, he
suggested to me that I should go to Stanford to spend a postdoc
year with Tom Merigan. As alternatives he suggested Johns
Hopkins (Baltimore) with Bob Wagner and Bronx (New York)
with Phil Marcus. The decision was easily made. After some
deliberation in 1967 with my future wife, Lili (whom I married in
1968), we decided to go to Stanford; to go over there, I got a
fellowship from Eli Lilly, including ﬁrst class fare for myself (with
PanAm) which I could easily convert into two economy tickets for
Lili and myself, and on 4 September 1968, three days after we
married, off we went from Brussels via London, to Los Angeles,
San Francisco, and ﬁnally, Palo Alto, the last segment of the trip
by helicopter. The stay at Stanford University was planned for one
year, but we liked it so much that we ﬁnally stayed for two years,
2 months and 3 weeks before we returned to Belgium at the end of
November in 1970. To support this stay at Stanford, I got a Lilly
fellowship for the ﬁrst year extended by a Damon Runyon
fellowship for the second year. The year 1967 had been a yearfull of discoveries, ﬁrst and most importantly, the fact that I fell in
love with Lili which would result in our becoming engaged and
subsequently married in 1968. From a more scientiﬁc viewpoint, a
very important breakthrough in 1967 was the induction of
interferon by double-stranded (ds)RNAs by Maurice Hilleman's
group at Merck (Fig. 3)4–7. The amounts of interferon induced by
dsRNAs exceeded by far those induced by polyacrylic
acid or pyran copolymer (Fig. 4), and for this discovery, as well
as the vaccines he developed at Merck, Maurice Hilleman
would have deserved the Nobel Prize, which, unfortunately, he
never won.
From September 1968 till November 1970, I spent together
with my wife Lili a marvelous time at Stanford University in the
Department of Medicine. My host at Stanford University was
Thomas Chandler Merigan. At Stanford I would focus, under the
guidance of T.C. Merigan (Fig. 5), on various aspects of interferon
induction. He left me free to work on whatever aspect I liked, on
the condition that it led to publishable results with me and T.C.
Merigan as co-authors. He showed an unbridable enthusiasm for
whatever result or ﬁnding I came up with, so that after 2 years at
Stanford I had managed to publish about 25 papers, all with T.C.
Merigan as co-author, two papers in Nature8,9, one in Science10,
and a couple others in such distinguished journals as JCI (Journal
of Clinical Investigation)11 and JMB (Journal of Molecular
Biology)12. I did not have other obligations except for working
hard (enjoying myself) in the laboratory and producing manu-
scripts, which at one occasion, after I had ﬁnished writing it, my
wife typed during the night, so that when T.C. Merigan appeared
in the ofﬁce the next morning at 9:00 am he found the manuscript
waiting for him at his desk. The paper was sent to, and published
in, the Journal of Immunology13. At Stanford, I had the (scientiﬁc)
luxury of attending, almost on a daily basis, lectures from the most
prestigious lecturers worldwide, but those leaving the most
unforgettable impression were those given by the members of
the Department of Biochemistry with Arthur Kornberg, Paul Berg
and a few others, who a few years later, would all be honored by a
Nobel Prize in either medicine (or physiology) or chemistry. I
attended their lectures as a free student, not being enrolled in any
(Ph.D.) program. At Stanford, I remember working day and night,
especially at night and weekends (Saturday and Sunday), because I
had then the scintillation counters free for use, so that I did not
have to sign up beforehand. On Monday evenings we (the
students) had to give seminars attended by the staff members of
Figure 3 Structure of poly(I)  poly(C).
Figure 4 Structures of polyacrylic acid, polymethacrylic acid and pyran copolymer.
An Odyssey in antiviral drug development 523the Department of Medicine, the most critical (and most feared)
being a certain Bill Robinson (at the time married to Harriet
Robinson) who worked on hepatitis B virus (HBV) infection. I
also remember Hugh McDevitt (Immunology) and Kenneth Vosti
(Bacteriology), and I became very well settled in Merigan's
laboratory with Johanna Lederer as his only secretary and Janet
Kulhanek as his only technician. T.C. Merigan even offered me
the opportunity to stay at Stanford (Medical School) as the head
of the Clinical Virology, which was then (November 1970) being
set up.
But, in the beginning of November 1970, Lili and I returned
back home from Stanford to Leuven, not without a few lectures I
gave on 2 November 1970 at NIH (with Robert Friedman as my
host), on 3 November at Johns Hopkins [with W.A. (Bill) Carter
and P.O.P. (Paul) Ts'O as my hosts] and on 5 November at du
Pont de Nemours (with Royce Lockart Jr. as my host). Back in
Leuven, I was not welcomed as the lost son who returned, exceptby my boss Prof. De Somer. He wished me a warm welcome, but
his assistants were somehow reluctant to see me back. De Somer
assigned me a laboratory that was just evacuated by Carlo Cocito
who had moved to the UCL in Woluwe and he had taken with
him all what was useful, so that the only materials left over was
mostly broken (or useless) furniture and glassware. When I went
to express my wrath to Prof. De Somer, he assured me I had to
get accustomed again to the Belgian way of life. When I told him
I needed help from a technician, he asked around, and found one,
Mrs. Anita van Lierde, who would remain my beloved technician
for the rest of my life, till her pension, at the age of 60, in 2006.
The least I could say was that, except for my boss, Prof. De
Somer, his assistants were not over-excited to see me back in
town. There was a tremendous beneﬁt; however, De Somer let
me work on whatever I liked, and this was at that time, at the end
of 1970, two things, induction of interferon by dsRNAs (double-
stranded RNAs)14 and inhibition of the reverse transcriptase
Erik De Clercq524(RT), which had just been discovered by Howard Temin and
David Baltimore15,16. At a Saturday night working in the
laboratory, I tried to repeat the experiments of Temin and
Baltimore, and conﬁrmed that it worked (I got TCA [trichloro
acetic acid]-precipitable counts). I must have told my wife later
that night, but she probably fell asleep when I tried to explain the
signiﬁcance of these ﬁndings. Since this eventful Saturday
evening, I would remain for my whole life attached to RT,
admiring Howard Temin for not only having discovered, but also
having predicted the existence of such enzyme. While I was
struggling in forgetting how nice life was at Stanford, and how
miserable it was in Belgium (Leuven), I suddenly had two
scientiﬁc lives in 1970, interferon induction by dsRNAs and the
RT which soon after had been discovered by Temin andFigure 5 Photograph of E. De Clercq and T. C. Merigan (Chemical
Engineerings News, June 1969, 17–18).
Figure 6 Symposium on synthetic nucleosides, nucleotides and polynuc
Germany, 3–5 May 1976.Baltimore, conﬁrmed by R. (Bob) C. Gallo, and was postulated
by Sol Spiegelman to be at the origin of all cancers, a tantalizing
hypothesis.
Back in Leuven, upon my return from Stanford, it took me
almost a year before I could get climatized again and I ﬁnally did. I
went into two directions, interferon induction by synthetic double-
stranded polynucleotides17, and RT inhibition by synthetic single-
stranded polynucleotides. I got into contact with David Shugar
(from Warsaw), who helped me from moving from the polynucleo-
tides to the direct antiviral activity of nucleosides, but through my
contacts with Bernhard Witkop18, and particularly Paul F. Torrence,
I remained hooked onto the polynucleotides, i.e., poly(I)  poly(A) 
poly(U)19, a triple-stranded RNA complex, that was not able to
induce interferon, and therefore of only academic interest. This was
one of my major research ﬁndings in the middle of the 1970s. This
ﬁnding was not going to elicit any practical value. My long-
standing collaboration with Torrence/Witkop on polynucleotides
inducing interferon was predestined to come to a premature end.
Around the 1975s, I was slowly moving from the polynucleotides
and their interferon inducing potential to the nucleoside analogues
and their direct antiviral effects. De Somer had indicated that he had
lost his faith in interferon (as President of the university, he was too
much absorbed by his many other duties) and he persuaded me to
leave interferon behind, in exchange for the nucleosides/nucleo-
tides. The meeting that I attended in Göttingen (Max Planck Institut
für Biophysikalische Chemie) in May 1976 (Fig. 6) determined the
further course of my life. I met there Antonín Holý, Dick Walker,
and together with several other nucleoside chemists, i.e., H.
Vorbrüggen, W. Pﬂeiderer, J. Montgomery, J. Moffatt, they re-
oriented my further scientiﬁc life towards the antiviral potential
of nucleosides/nucleotides. From this symposium originated a
number of collaborations which would later yield a wealth of
new antivirals, 2,3-dihydroxypropyladenine (DHPA), bromovinyld-
eoxyuridine (BVDU), (S)-9-(3-hydroxy-2-phosphonylmethoxypro-
pyl)adenine (HPMPA), (S)-1-(3-hydroxy-2-phosphonylmethoxy-
propyl)cytosine (HPMPC), 9-(2-phosphonylmethoxyethyl)adenine
(PMEA)…, so that Göttingen 1976 remains anchored in my
memory as the year when I made my greatest discovery, not that
of any compound, but the discovery of so many distinguishedleotides, Max-Planck-Institut für Biophysikalische Chemie, Göttingen,
Figure 8 Picture of Prof. P. De Somer when receiving Pope John
Paulus II in Leuven on 18 May 1985.
An Odyssey in antiviral drug development 525chemists, who would later synthesize all the compounds that revo-
lutionized the antiviral ﬁeld. In particular, the collaboration with A.
Holý, which then started as East-West collaboration, would later
evolve as the prototype of how chemistry and biology/medicine,
when joining forces with industry, would foster successful antiviral
drug development.
The ﬁrst years, after my return from Stanford University, at the
Rega Institute were explorative and uncertain as to whatever the
future was yielding. A memorable day was 9 May 1975, when Raf
(Rafaël), my son was born. As we married in 1968, it took 7 years
before my greatest achievement ever went “into press”, but it was
especially Lili's greatest achievement, and she took so extreme
care of our son. This event overshadowed all my scientiﬁc
endeavors, although it was already apparent at that time that my
interest was slowly shifting from interferon (inducers) to nucleo-
side analogues and RT inhibitors. Suramin was an example of the
polyanionic type of compounds which I found active as an RT
inhibitor. I kept this as a little secret to myself, investigating
whether suramin, to see if Sol Spiegelman was right, could be
anticipated to exhibit anticancer activity. Around 1975, I anxiously
looked into the activity of suramin against leukemia in mice. It
had, however, no activity and I abandoned the suramin approach,
until in 1978, Bob Gallo, when visiting our lab, encouraged me to
publish the original results of suramin as an RT inhibitor, which I
ﬁnally did in Cancer Letters (1979)20 (Fig. 7). I then forgot
suramin, thereby losing my faith in RT as a possible component in
the origin of cancer. My dream to ever ﬁnd a cure for cancer,
certainly a cure based on suramin, was obviously not going to be
fulﬁlled, but life around me was going full speed, and in 1981, the
year that the disease AIDS was identiﬁed, Prof. De Somer was
elected again (his last time) as President of our university. I
participated in the house party celebrating his re-election on 21
June 1981. It would be the last party ever at his mansion. One year
later, on a trip to South East Asia, he fell sick with an intestinal
obstruction. He recovered from the abdominal surgery, being it for
only a few years, and on 17 June 1985, he rather unexpectedly
died from a lung embolism complicating a second abdominal
intervention. It happened that at the time I was in Czechoslovakia,
with Holý (on Sunday). The tragic news reached me on Tuesday
19 June, in Bechyne, at the meeting that I then attended together
with Vladimir Vonka. I could not believe that De Somer had died.
For me he simply could not die, and as of today, I still think it was
a nightmare from which he would ultimately resurrect.
The death of De Somer (17 June 1985), at the age of 67, just
one month after he had hosted the visit of the Pope in Leuven
(Fig. 8), was a deadly tragic event: it was a great loss for the
university, but even more so, for his family, colleagues and
myself. He was an “icon”, who just could not die; his death
proved he was not immortal. Leaving us, his disciples, behind was
simply unacceptable. At the Institute, I was quickly canonized asFigure 7 Structural fohis successor, the youngest of his disciples, my competitors being
Alfons Billiau, Hubert Vanderhaeghe, Hendrik Eyssen and Michel
Vandeputte. They all wanted to be De Somer's successor at the
institute, whereas I did not envy this position, but ﬁnally, my
colleagues selected me as De Somer's successor. In 1985 I was
parachuted in a position I did not want, I became Chairman
(Director) of the institute, not knowing of the implications that
were lying ahead.
In no time I was myself surrounded by clever disciples: Piet
Herdewijn, Jan Balzarini, Rudi Pauwels, Robert Snoeck, Graciela
Andrei, Lieve Naesens, Johan Neyts, Dominique Schols and
Christophe Pannecouque. A nice “family”, quite coherent, I thought,
each excelling in their own ﬁeld, which they had developed, ﬁrst
with my guidance, later, independently thereof. R. Pauwels left the
group to start Tibotec/Virco, and later Biocartis. In leaving the
family, in 1994, he made the most successful move, admittedly with
the support of Dr. Paul Janssen. The others stayed on board, and still
are, but in the future, they will have to ﬁght for their own destiny.
Up till my obligatory retirement in 2006, and even thereafter, I felt
as the conductor (dirigent) of an ever expanding chorus of dedicated
scientists, each trying to make his own way, with “a chef
d'orchestre” still trying to keep his leading role, thereby witnessing
how the different members of his team got dispersed in different
directions: J. Balzarini in the biochemistry of the acyclic nucleoside
phosphonates, and later from the 2000s, the antiviral potential of
glycopeptide antibiotics; D. Schols, through the role of chemokine
receptors (CXCR4, CCR5) in HIV infection, ﬁnding a new future in
the microbicides for the prevention of HIV infections (an ever self-
perpetuating approach and never-disappearing strategy to prevent
HIV infections); J. Neyts, who quickly made the step to veterinary
(virological) medicine, thereby never giving up on the potential inrmula of suramin.
Figure 9 Collaborators of Prof. E. De Clercq.
Erik De Clercq526human medicine for those compounds targeting ﬂaviviridae (i.e.,
dengue, yellow fever, hepatitis C virus [HCV]) and picornaviridae
(i.e., polio and rhino), thereby tackling almost all viruses except for
the human immunodeﬁciency virus (HIV); G. Andrei and R.
Snoeck, who got united in our laboratory, working together on
a number of viruses, the others did not want to work with,
cytomegalovirus (CMV), varicella-zoster virus (VZV), human
papilloma virus (HPV), poxviruses and, later on, polyomaviruses;
L. Naesens, who always remained faithful to her predestined
vocation, ﬁrst human herpes virus type 6 (HHV-6), later inﬂuenza
virus; and C. Pannecouque, originally educated by P. Herdewijn, but
then transplanted to our laboratory to lead the screening of anti-HIV
compounds. And C. Pannecouque is still doing so, even after my
term as head of the laboratory elapsed (in 2006, to be exact).
Looking back at what history generated, I should be proud of the
progeny I left behind (Fig. 9), J. Balzarini, D. Schols, J. Neyts,
G. Andrei, R. Snoeck, L. Naesens, C. Pannecouque, who stayed,
and R. Pauwels, who left. My achievement? The luck for keeping
them, except for Rudi Pauwels, together at the Rega Institute. There
were other indelible personalities that, with immense satisfaction, I
ever worked with, including my currently best Japanese friend,
Masanori Baba, former Vice-Rector at Kagoshima University, and
his boss, Shiro Shigeta (formerly, President of the Medical College
at Fukushima), Chong-Kyo Lee at Daejeon (South Korea) and my
old student from the KULAK, Zeger Debyser, and his once-upon-a
time co-worker, Myriam Witvrouw, whom I remember well from
the exciting days their careers began to blossom.Time for reﬂection
I started my career with the hope to discover at least one anticancer
drug, but I did not discover any. This failure was, to some extent,
compensated by the discovery of a few antiviral drugs. Serendipity
played a predominant role in how these compounds emerged.
Aminoacyl esters of acyclovir (i.e., glycyl- and alanyl-acyclovir)
were designed to increase the aqueous solubility of acyclovir; next
in the series of aminoacyl esters of acyclovir was the valine
ester; it later proved to be the ideal candidate prodrug of acyclovir
to increase its oral bioavailability, thus substantiating its clinicaluse in the oral treatment of herpes simplex virus (HSV) and VZV
infections. BVDU was conceived as a successor for idoxuri-
dine (IDU) and triﬂuridine (TFT), the ﬁrst two 5-substituted
2′-deoxyuridines ever to be launched for the topical treatment of
herpetic eye infections; BVDU became the runner-up for the
treatment of VZV infections (herpes zoster). With stavudine (d4T),
we had at hand what was at a certain time the gold standard for the
treatment of HIV infections (AIDS); however, d4T was discovered
at three places at the same time (Leuven, Yale and Tokyo), which
engendered some international animosity in the old days. In the
meantime, other HIV inhibitors that outweighed d4T were
discovered in both potency and safety, the most prominent being
TDF (tenofovir disoproxil fumarate). Tenofovir has been the life-
time achievement of the Holý Trinity, i.e., Antonín Holý, myself
and John C. Martin (Fig. 10). For 10 years or more, it has stood
up as the cornerstone for the treatment of HIV infections, and
for its prevention as well, either by itself as Vireads, or in
combination with other compounds, i.e., Truvadas, Atriplas,
Compleras/Evipleras, or Stribilds. TDF (Vireads) has now
become the gold standard for the treatment of both HIV and
HBV infections, but, in the future, it will likely to be replaced by a
new tenofovir prodrug, TAF (tenofovir alafenamide), which, like
its predecessor, TDF, may evolve as the drug of choice for the
treatment of both HIV and HBV infections.My comments
I was not born to be a researcher (or “scientist”), but born to be a
teacher (or “professor”). What I learned from my parents were the
virtues of hard working, perseverance, honesty and enthusiasm.
Two scientiﬁc discoveries made me particularly enthusiastic; ﬁrst,
the discovery by Maurice Hilleman's group at Merck that inter-
feron could be induced by double-stranded RNA, and second, the
discovery of the reverse transcriptase by Temin and Baltimore. As
a young student in medicine, I had always been dreaming of
discovering a cure for cancer, and here, I had two potential leads:
interferon, originally discovered because of its antiviral activity,
had become extremely popular in the 1970s as a potential
anticancer agent; and the reverse transcriptase which was
Figure 10 The Holy Trinity in Olomouc (a) and the Holý Trinity
representing chemistry, biomedicine and industry (b).
An Odyssey in antiviral drug development 527originally (also in the 1970s) considered as the key enzyme in the
origin of cancer (proposed by Sol Spiegelman), before its role was
established (in the 1980s) in the origin of AIDS. In addition to
perseverance and enthusiasm, ﬂexibility may seem of intrinsic
value as it would allow to re-orient the research to new frontiers
(i.e., AIDS) which were not recognized initially.II. Period 1975–2005
In 1979 I described the anti-HSV activity of BVDU (brivudin),
which would later be marketed as the most potent antiviral
drug ever developed for the treatment of VZV infections. In
1983 followed the amino acid esters of acyclovir, the valine
ester would ultimately emerge as the successor of acyclovir for
the treatment of HSV and VZV infections. d4T, discovered in
1987, would be the fourth nucleoside reverse transcriptase
inhibitor (NRTI), following 3′-azido-2′,3′-dideoxythymidine
(azidothymidine, AZT), 2′,3′-dideoxyinosine (ddI) and 2′,3′-
dideoxycytidine (ddC), developed for the treatment of HIV
infections. Then followed in 1989 and 1990, 1-[(2-hydroxye-
thoxy)methyl]-6-(phenylthio)thymine (HEPT) and tetrahydro-
imidazo[4,5,1-jk][1,4]-benzodiazepine-2(1H)-one and -thione
(TIBO) were discovered as the ﬁrst non-nucleoside reverse
transcriptase inhibitors (NNRTIs), which, however, were not
developed as anti-HIV drugs. Instead, a nucleotide analogue,
tenofovir, originally described in 1993, as its prodrug form
(TDF), became the cornerstone for HIV treatment. After being
launched as Vireads in 2001, it was in combination withemtricitabine marketed as Truvadas for HIV treatment in
2004, and extended in 2006 to efavirenz (Atriplas), which was
then replaced in 2011 by rilpivirine (Compleras/Evipleras),
and extended to the quadruple pill containing TDF, emtricita-
bine, elvitegravir and cobicistat (Stribilds) in 2012. Till 2006
when I was forced to retire, I had more than 200 collabora-
tions worldwide, my scientiﬁc publications peaked at some 80
per year (exactly 80 in 1991), and my teaching duties
amounted up to 10 hours per week, and this lasted over a
period of 37 years (from 1972 to 2009).2.1. Acyclovir
The discovery of acyclovir as an antiviral agent in 1974 at
Burroughs Wellcome in the UK (Beckenham) by Peter Collins
and John Bauer meant a milestone in the antivirals' saga21. The
compound was only published 3 years later (in 1977) when
Gertrude B. Elion and her coworkers22 in the US (Research
Triangle Park) revealed in the December 1977 issue of PNAS
(Proceedings of the National Academy of Sciences of the United
States of America) that acyclovir owed its antiherpetic selectivity
to a speciﬁc phosphorylation by the herpesvirus-encoded thymi-
dine kinase. Schaeffer et al.23 would further describe the antiviral
potential of acyclovir in the April 1978 issue of Nature. This
meant a milestone in the era of antiviral drug development as
acyclovir represented the ﬁrst speciﬁc antiviral compound ever
described. It would later emerge as the “gold standard” for the
treatment of HSV infections, and its use would be extended to the
treatment of VZV infections. Although not recognized in this
capacity as such, acyclovir would later contribute to the Nobel
Prize in physiology or medicine, attributed to Elion and Hitchings
in 1988 (their Nobel Prize was formally recognized for their
contributions to antimetabolites in general). Having described
DHPA as a broad-spectrum antiviral agent in Science24, not acting
in the same way, but yielding a similar result as acyclovir, I was
one of the ﬁrst witnesses to appreciate the success bestowed to
acyclovir. In no time, acyclovir conquered the world of antivirals,
leaving its potential competitors, ﬂuoroiodoaracytosine (FIAC)
and bromovinyldeoxyuridine (BVDU), far behind. These compe-
titors would either disappear from the scene like FIAC or later
follow a meandrous path in their development like BVDU.
Acyclovir would clearly excel as the leader of the gang, gaining
general acceptance in all countries where its application was
deposited. One of these countries was mine, Belgium. As of today,
in 2014, acyclovir has remained the preferred drug for the
treatment of both HSV and VZV infections. The professor of
medicinal chemistry, H. Vanderhaeghe must have foreseen this
fate when back in the early 1980s, he convinced me of the
potential importance of the acyclovir esters, i.e., glycinyl (glycyl)
and alaninyl (alanyl) esters of acyclovir (Fig. 11) that may play a
superior role to acyclovir because of their increased aqueous
solubility compared to the parent compound25,26. I thought that the
derivatization of an existing compound by modifying it to its
prodrug was not very innovative. I accepted his arguments in
trying to sell this prodrug to the original producer of acyclovir,
Burroughs Wellcome (Beckenham, UK). It made me travel, with
Prof. De Somer (then rector) as my companion, to the UK to
introduce both the Rega Institute and our plans, and it eventually
worked out splendidly. Burroughs Wellcome (BW) in 1993 agreed
to buy the rights for the acyclovir amino acyl esters for a small
lump sum and even smaller prospect on potential royalties, and
Figure 11 Structures of (val)acyclovir.
Figure 12 Structure of brivudin (BVDU).
Figure 13 Structure of stavudine (d4T).
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ever (co)discovered. The amino acyl ester of acyclovir, valacy-
clovir (Valtrexs, Zelitrexs) (Fig. 11), would later supersede
acyclovir because of its better oral absorption, but this advantage
was not predicted by our original observations. Our original patent
claims on the amino acyl esters of acyclovir were therefore not
universally granted (i.e., in the US they were not), but, with my
co-inventors, Prof. H. Vanderhaeghe and Dr. (later Prof.) R.
Busson, we were granted patent rights on valacyclovir in the rest
of the world. These rights were granted from 1995 till 2002, when
valacyclovir turned generic.
2.2. BVDU (Brivudin)
Whereas acyclovir was originally synthesized in the US (Howard
Schaeffer), and its antiviral activity originally demonstrated in the
UK (Peter Collins/John Bauer), BVDU (Fig. 12) was originally
synthesized in the UK (Phil Barr/Stan Jones/Dick Walker), its
antiviral activity was ﬁrst demonstrated in our laboratory at the
Rega Institute. I divulged its antiviral potential at a meeting in
Prague (10–12 July 1978), a few months after the antiviral activity
of acyclovir had been described in Nature (April 1978). The full
paper (sponsored by Bernhard Witkop) was published in the
PNAS in 197927. As compared to acyclovir, BVDU was slightly
more potent against HSV type 1, much less active against HSV
type 2, but clearly much more potent against VZV. In fact, BVDU
proved about 1000-fold more potent than acyclovir against VZV in
vitro (cell culture). Although an anecdotal case report study
published in 1980 in the British Medical Journal with four
patients had already pointed to the potential efﬁcacy of BVDU
in the treatment of VZV infections (herpes zoster)28, it would take
another 20 years before the compound would be ofﬁcially
approved in a number of European countries (Germany, Italy
and Belgium); but it would never be approved in the UK or USA.
The main reason for this delay is that the Company G.D. Searle,
who had originally taken the license on BVDU, decided in 1984
not to further pursue its development because of its carcinogenic
potential (liver tumors) if administered perorally at 1 g/kg/day for
1 year to a special breed of rats that were highly sensitive to this
event (whereas humans would only need treatment with 125 mg
per 70 kg per day for at most 7 days). This schedule has obviously
never proven carcinogenic in humans. The fact that G.D. Searle
(later Monsanto) was principally operative in the US and the UK
explains why BVDU never made it to the market in thesecountries. That BVDU made it to the market in Germany and
several other European countries was actually due to the success
obtained with BVDU in the DDR (East Germany), where it had
been synthesized in Berlin Buch by Peter Langen/Dieter Bärwolff,
evaluated by Peter Wutzler (Erfurt) and licensed to Berlin-Chemie.
After the DDR ceased to exist in 1989, the rights on BVDU would
eventually be transferred from Berlin-Chemie to Menarini, a
private Italian company headquatered in Florence. As mentioned
above, for the treatment of herpes (oral) zoster, a daily dose of
125 mg BVDU for 7 days (that may be reduced to 5 days) sufﬁces,
whereas acyclovir and valacyclovir have to be given at 4 g or 3 g
per day, respectively. BVDU can also be administered as eye
drops in the treatment of herpetic cornea infections (herpetic
keratitis) (work pioneered on by my good friend, Prof. Prabhat
Maudgal)29–32 and ointment in the treatment of cold sores of
(herpes labialis), but, despite the anecdotal successes obtained in
these conditions, BVDU has never been commercialized for these
indications.
2.3. d4T (2′,3′-Didehydro-dideoxythymidine)
d4T (stavudine, Zerits) (Fig. 13) was ofﬁcially discovered
simultaneously at 3 different sites, Yale University, Rega Institute
and Tokyo (Yamamoto's Laboratory). To be honest, we at the
Rega Institute were the ﬁrst to recognize d4T (which we originally
called 2′,3′-didehydro-thymidinene) as an anti-HIV agent with the
potential to combat HIV infections. I have never known what
exactly happened in Japan, till the paper of Hamamoto et al.33 was
published in the June issue of Antimicrobial Agents and Che-
motherapy (1987). Piet Herdewijn had synthesized the compound
by November 1985 within one month after the PNAS paper
(October 1985) of Mitsuya et al.34 had appeared on the inhibition
An Odyssey in antiviral drug development 529of the infectivity of HIV (then called HTLV-III/LAV) by AZT. I
sent the compound overseas to J. Balzarini, who had just started
from December 1985 to work in Sam Broder's laboratory at
National Cancer Institute (NCI). Followed the technique devel-
oped by Hiroaki Mitsuya, using ATH8 cells, which had proven
successful to demonstrate the anti-HIV activity of AZT, and later
of ddC and ddI as well35 (but which for some reasons were never
clariﬁed), did not prove particularly useful to demonstrate the anti-
HIV activity of d4T. From August 1986, Masanori Baba had
joined our research team in Leuven and I asked him to look again
into the anti-HIV activity of d4T, now using a different cell line,
MT-2. He found an astonishingly potent anti-HIV activity. By
November 1986, we had already completed our paper which we
submitted to Dr. Sols who was the editor of Biochemical and
Biophysical Research Communications (BBRC) for publication in
the journal. The paper was accepted right away and ﬁnally
published in the journal on 17 January 198736. The paper had
also been sent (in November 1986) to our patent attorney, a certain
Mr. Bruin from Arnold and Siedsma (the patent ofﬁce in Den
Haag), who let the paper sitting on his desk, without any due
action, for 2 months in his ofﬁce, before ﬁling the patent
application. In the meantime, Prusoff and Lin (from Yale) had
submitted their patent application (sometime in December 1986).
In these days I was often visited by Julius Vida, Director (later
President) of licensing at Bristol-Myers (several years later it
became Bristol-Myers Squibb [BMS]), who expressed the desire
of Bristol-Myers to further develop d4T as an anti-HIV drug and to
license the compound from whomever got the valid patent (Yale or
Rega). I realized that ﬁghting Yale University from a small place
in a small country was like ﬁghting David against Goliath, an
“impossible mission”. We had been clearly the ﬁrst to demonstrate
the anti-HIV activity of d4T (as a matter of fact, Bill Prusoff never
had worked with HIV in his lab); his patent was based only on the
anti-murine retrovirus activity of d4T: this appeared sufﬁcient for
the patent examiners to surmise that the compound should be
effective against AIDS, whereas in our case the patent examiners
reasoned that activity against HIV in cell culture could not be
extrapolated to activity against HIV in the patient. This was the
rather enigmatic verdict of the US patent ofﬁce thus assigning the
patent rights to Yale, which then transferred the rights to Bristol-
Myers, … and d4T turned out to be a success story, which, at a
certain time, yielded yearly sales of 700,000 US dollars. I could
gladly accept Bill Prusoff's success with d4T. He had missed his
success with IDU (5-iodo-2′-deoxyuridine) for which he was the
sole discoverer, because Yale had neglected to protect the
compound. They did so for 5′-amino-5-iodo-2′-deoxyuridine
(AIU), but this compound did not become a successful antiviral.
Finally, d4T became a success, but for sure some Belgians and
Japanese did not indulge in Yale's success. I valued my personal
relationship with the Prusoff's (Bill and Brigitte) higher than any
possible rewards from patent income and I consented with the
adulation of Bill Prusoff as the godfather of antivirals, until he
passed away at the age of 90 on 3 April 2011.2.4. The dawn of the anti-HIV antivirals
In 1985, sometime in the summer, a young pharmacist, by the
name of Rudi Pauwels, knocked at my door. He actually
introduced himself ﬁrst at the institute's reception desk where he
was met and ousted by our Secretary-in-Chief, Mrs. Jane Putzeys
(a ﬁrst reaction from Jane to deter strangers, so that they would notget too easy access to the Sanctuary of what she considered the
temple of God (Prof. Piet De Somer). Rudi, nevertheless, broke the
ban, as he would do repeatedly at later occasions, penetrated into
my ofﬁce and expressed his desire he would like to come to work
for me. Why Rudi had selected me was not immediately clear.
Perhaps he had some hidden plans, but a cure for AIDS was
certainly not on top of his original list (principally because HIV
was barely known or appreciated at the time). I proposed originally
to Rudi to work on 2-5A as mediator of the action of interferon,
but he proposed that HIV would be a more attractive subject. I had
my co-worker, J. Balzarini, sent to the US to learn how to handle
HIV in Sam Broder's laboratory with Hiroaki Mitsuya, whereas in
the meantime, Rudi Pauwels, came to work in our laboratory with
the aim to develop the cure (ideal treatment) for HIV. Rudi
Pauwels was a pharmacist, who had an unequalled talent for
robotics and technology, besides being an entrepreneur: he became
highly regarded by Paul Janssen, and I could only conﬁrm Dr.
“Paul's” insight. J. Balzarini was supposed to get some training
with Thomas Kalman in Buffalo (New York, US) on the
metabolism of nucleoside analogues and their mechanism of
action against cancer, but the emergence of suramin as an RT
inhibitor crossed these plans. Based on my observation in 1975
(published in 1979)20 that suramin appeared to be a rather potent
inhibitor of RT, Sam Broder at the suggestion of R.C. Gallo with
the help of H. Mitsuya tested whether suramin would inhibit the
infectivity of HIV (then called HTLV-III/LAV), as the RT was
assumed to play a key role in the replication of HIV. Suramin
actually inhibited the replication of HIV and this was originally
attributed to its inhibitory effect on the RT37 (although in later
studies it was shown that suramin, being a polyanionic compound,
also inhibited virus adsorption to the host cells)38. S. Broder called
me at home to inform me that suramin was inhibitory to HIV
infectivity (this apparently happened after he had received news
from Science that his paper had been accepted37 and in this phone
conversation he invited me to come over to the NCI to spend a
year (sabbatical) further following-up on suramin and other RT
inhibitors for their anti-HIV activity. As I felt I could not just leave
the laboratory behind and interrupt my teaching in Kortrijk (at the
KULAK), I declined the invitation but, instead, convinced
J. Balzaini to take up this assignment and from the ﬁrst December
1985 he went over for a year to work in Sam Broder's laboratory
on the anti-HIV activity of new nucleoside analogues. Most of
these nucleoside analogues had been synthesized by P. Herdewijn
in our institute and he had started his project in November 1985
just after the paper of Mitsuya in PNAS (October issue of 1985)
had been published that AZT proved inhibitory to the infectivity of
HIV34. One of the compounds P. Herdewijn had ﬁrst synthesized
was d4T, but as J. Balzarini used the ATH8 cells routinely used by
Mitsuya in Broder's laboratory, he did not ﬁnd high potency with
d4T (or certainly not enough activity to justify taking a patent).
From the end of 1985, after J. Balzaini had left for the US,
R. Pauwels started to work in our laboratory, originally on the role
of 2-5A in the mode of action of interferon, but he soon switched
to HIV and by the middle of 1986 he had set up the assay systems
for HIV which he would later gradually perfectionize. Thus was
set up the AIDS laboratory, which was later joined by D. Schols
and M. Baba (both from 1986). In the AIDS laboratory they would
use MT-2 cells, which M. Baba used to demonstrate the potent
anti-HIV activity of d4T, and later in 1987 the anti-HIV activity of
HEPT. At the end of 1987 we knew of the anti-HIV activity of
HEPT, but we did not know how it really worked: as an (acyclic)
nucleoside analogue, there was no precedent of any other acyclic
Erik De Clercq530nucleoside analogues that would act similarly, so that in the
beginning I thought the HEPT sample was contaminated by a
known nucleoside analogue of the AZT type, especially when we
found that HEPT had only activity against HIV-1, but not -239,40
Dough Richman had just published in Antimicrobial Agents and
Chemotherapy (AAC)41 that AZT was more active against HIV-1
than -2, an observation that later on was not conﬁrmed. At the end
of 1989, we published that HEPT (Fig. 14) was a newly identiﬁed
anti-HIV compound with an unknown mechanism of action. The
mechanism of action would be resolved in 1990, and 1991. HEPT
was found to act as an NNRTI inhibiting HIV-1 by an allosteric
interaction with a non-catalytic site, just like the TIBOs would do.
The TIBOs (Fig. 15) were discovered as the result of an extensive
collaboration I had started in 1988 with Dr. Paul Janssen with the
ambitious goal of discovering a “cure” for AIDS, which, according
to Dr. Janssen, could not be that difﬁcult. Little did he know that it
would prove to be an Herculean task.2.5. NATO/FEBS meetings
Together with Dick Walker (University of Birmingham, UK), I
organized three NATO Advanced Study Institutes (ASIs). So as to
allow participants from Eastern Europe, these meetings were also
FEBS (Federation of European Biochemical Societies) Advanced
Courses. These NATO/FEBS meetings invariably lasted for 12
days and took place on 7–18 May 1979 in Sogeta, close to Urbino,
Italy (this meeting was also co-organized by Fritz Eckstein
(Göttingen, Germany)), on 19 June–2 July 1983 in Les Arcs,
France, and on 10–23 May 1987 in Il Ciocco, close to Barga, Italy.
These meetings were mainly focused on the design of new
antiviral agents, particularly nucleoside analogues. They were
limited to about 100–120 attendants, originating from either
NATO countries, FEBS countries, or other countries such as
Japan. NATO rules had to be implemented: that means that as
many NATO countries as possible should be represented, and noFigure 14 Structure of HEPT (1-[2-(hydroxyethoxy)methyl]-6-(phe-
nylthio)thymine).
Figure 15 Structures of TIBO R82150, TIBO R82913, TIBO R86183 (teNATO country should exceed 20% of the total, which was a
serious problem for the US (but not for Luxemburg, of course).
The money (travel, subsistence) had to be meticulously divided
(NATO money to NATO participants, FEBS money to FEBS
participants, and the remaining (industrial) money to the rest of the
world). In these East-West (Iron Curtain) times, funds had to be
carefully distributed so that, for instance, no NATO money was
ever allocated to an East European, Polish or East German. I
personally enjoyed puzzling with the funds thus taking care of the
administration, whereas my colleague, Dick Walker, enjoyed
running the programme and handling the talking (his English
(British) was supposed to be better than mine). As we had to get
together for the full two weeks, the mean purpose of these
meetings was that they not only stimulated the exchange of
scientiﬁc knowledge, but also fostered personal social contacts
which quite often would later last for the rest of our lives. The
1987 Il Ciocco meeting would be the last of the three NATO
meetings. From the ashes of the NATO meetings then arose, as a
Phoenix, the ICAR (International Conferences on Antiviral
Research) meetings, which from 1988 (Williamsburg) and 1990
(Brussels) would subsequently held annually: 1991 (New Orleans),
1992 (Vancouver), 1993 (Venice), 1994 (Charleston), 1995 (Santa Fe),
1996 (Urabandai, Japan), 1997 (Atlanta), 1998 (San Diego), 1999
(Jerusalem), 2000 (Baltimore), 2001 (Seattle), 2002 (Prague), 2003
(Savannah), 2004 (Tucson), 2005 (Barcelona), 2006 (Puerto Rico),
2007 (Palm Springs), 2008 (Montreal), 2009 (Miami), 2010 (San
Francisco), 2011 (Soﬁa, Bulgaria), 2012 (Sapporo, Japan), 2013 (San
Francisco), 2014 (Raleigh) and 2015 (Rome). The original NATO rule
(no one NATO country should represent more than 20% of the
attendants) was quickly abandoned with roughly 70% (two-thirds) of
the attendants being US citizens. This also explains why the ICAR
meetings are classically held for two years in a row in the US,
alternating with one outside the US.2.6. Francqui Prize
As a young researcher devoting his whole career to science, one is
not immune to recognition by his peers, reﬂected by scientiﬁc
prizes. In Belgium, the most prestigious is the Francqui Prize
attributed to promising researchers under the age of 50 in three
alternating disciplines: (i) medicine, (ii) humanities (i.e., linguis-
tics, psychology, etc) and (iii) positive sciences (physics, mathe-
matics, chemistry, etc). Every year the King of Belgium hands
over this prize on behalf of the Francqui Foundation. This means
that for each of the three prizes, until the age of 50, every third
year the opportunity arises to compete for the prize. My boss, Prof.
P. De Somer, alerted me to this possibility for the ﬁrst time in
1978. I felt at that time too young and not sufﬁciently qualiﬁed,trahydroimidazo[4,5,1-jk][1,4-benzodiazepin-2(1H)]-one and -thiones).
Figure 17 Structure of emtricitabine (Emtrivas).
An Odyssey in antiviral drug development 531but he convinced me and I competed and lost. The winner was a
certain Nihoul from the University of Liège, but the tone was set
and I competed again for the 1981 prize; this time I was introduced
by Prof. Walter Fiers. I lost again, at this occasion the winner was
André Trouet whom was sponsored by the 1974 Nobel Prize
laureate Christian de Duve. For the 1984 prize, I was nominated
again by W. Fiers, but a few weeks before the jury reached their
verdict, two things happened that completely annihilated my
chances: (i) BVDU, the antiviral drug that I had discovered was
stopped for further development by G.S. Searle, and (ii) my
competitor, Désiré Collen got a breakthrough paper for the
discovery of his drug, tissue plasminogen activator (TPA), in the
New England Journal of Medicine42. No wonder, Désiré got the
Francqui Prize in 1984. With André Trouet and Désiré Collen out
of the way, I reckoned I should have a fair chance in 1987, and
this time, I had secured the help of Peter Wildy, professor of
pathology at Cambridge, to defend my case at the deliberations of
the jury, but, as in a Greek tragedy, Peter Wildy whom I had met
several times at WHO meetings, died a fortnight before the jury's
meeting, and the Prize 1987 went to a certain Urbain from the
Université Libre de Bruxelles for the discovery of the anti-
idiotypic antibodies (a discovery actually made by Jerne, for
which Jerne got honored by the Nobel Prize). I then put all my
hope to the 1990 Francqui Prize, which that year coincided with
the NFWO Prizes given every 5 years (so that both Prizes coincide
only every 15 years). I had counted on the help of Prof. Hans
Rosenthal (Charité, Berlin). He would defend me in the two juries
which assembled on two consecutive days, just before I organized
the 3rd International Conference on Antiviral Research (ICAR) in
Brussels on 22–27 April 1990. Hans Rosenthal called me at home
to inform me that I had missed both prizes (the Francqui 1990
Prize went to Thierry Boon-Lateur, who was once again the
disciple of Christian de Duve and the NFWO 1990 Prize was
awarded to my colleague A. Billiau). I broke into tears when
learning the double-sad news, just a few hours before I had to
confront my colleagues attending the ICAR meeting. Because of
the age limitation, I could never compete again for the Francqui
Prize. The NFWO Prize, then renamed FWO (Fonds voor
Wetenschappelijk Onderzoek) Prize, I would eventually get in
2000. The jury member defending my case was Hugh J. Field from
Cambridge, after I had been introduced by Paul Janssen and
Maurice Hilleman.Figure 16 Structures of (R)-PMPA (tenofovir2.7. Antonín Holý
At the Symposium on Synthetic Nucleosides, Nucleotides and
Polynucleotides, Max-Planck-Institut für Biophysikalische Chemie
in Göttingen, which was held on 3–5 May 1976, I made the
biggest discovery of my life, the discovery of a pleiade of
nucleoside chemists, the primus inter pares being Antonín Holý
from the Czechoslovak Academy of Sciences, active at the
Institute of Organic Chemistry and Biochemistry (IOCB) at
Flemingovo námestí in Prague. It was hardly predictable that this
apparently accidental encounter marked the beginning of an almost
four decades' long collaboration that would lead to almost ten
marketed products: (i) DHPA (Duviragels) for the treatment of
herpes labialis, (ii) cidofovir [(S)-HPMPC] (Vistides) for the
treatment of various DNA virus infections, (iii) adefovir (PMEA),
in its prodrug form, adefovir dipivoxil (Hepseras), for the
treatment of HBV infections; (iv) tenofovir [(R)-PMPA], in its
prodrug form, tenofovir disoproxil fumarate (Vireads, TDF)
(Fig. 16) for the treatment of both HBV and HIV infections,
(v) TDF in combination with emtricitabine (Truvadas) (Fig. 17)
for both the therapy and prophylaxis of HIV infections, (vi)
TDF in combination with emtricitabine and efavirenz (Fig. 18)
(Atriplas) for the therapy of HIV infections, (vii) TDF in com-
bination with emtricitabine and rilpivirine (Fig. 19) (Compleras,
Evipleras) for the therapy of HIV infections, (viii) TDF in
combination with emtricitabine, elvitegravir and cobicistat) and tenofovir disoproxil fumarate (TDF).
Erik De Clercq532(Fig. 20), again for the treatment of HIV infections, and, forth-
coming, (ix) tenofovir alafenamide (TAF), in combination with
emtricitabine, elvitegravir and cobicistat, for the treatment of HIV
infections. This made (R)-PMPA and/or its oral prodrug, TDF, the
most successful drug ever developed for the treatment of AIDS,
and it owed its success to the ingenuity of the chemist, A. Holý,
who ever synthesized the compound, but also to the foresight of
the industrialist, by chance also a chemist, John C. Martin, who
brought it to the market, and the medical doctor (myself) who
served as the go-in-between. Based on this triangle, which I
rightfully compared to the Holý Trinity, inspired by the Holy
Trinity monument in Olomouc, as one of the favorite cities of A.
Holý, the Holý Trinity stands as an example of the successful
interaction in (antiviral) drug development, the chemist, the
biologist, and the industrialist. Unfortunately, the Holý Trinity
lost on 16 July 2012, with the death of Antonín Holý, the basic
reason for its existence, but perhaps not really if we still continue
to commemorate the spiritual existence of the Holý Trinity.Figure 19 Structure of rilpivirine (Edurants).
Figure 20 Structures of elvitegr
Figure 18 Structure of efavirenz (Sustivas).2.8. Collaborations
Antonín Holý and John C. Martin excelled among the numerous
collaborations I had built up during the course of my career. Most
of these collaborators were (inorganic) chemists, spread over the
5 continents of the world. It started with Fritz Eckstein (Göttingen,
Germany) when I was still working in Merigan's laboratory at
Stanford, but it would quickly extend upon my return to Leuven to
David Shugar (Warsaw, Poland), Paul F. Torrence and Bernhard
Witkop (NIH, Bethesda), Morio Ikehara (Osaka, Japan), Shiro
Shigeta (Fukushima, Japan) and many others. At the height of
these collaborations I had developed a network of more than 200
collaborations, spreading over the following countries (in alpha-
betical order): Argentina, Armenia, Australia (G. Holan), Austria
[H. Griengl (Graz); G. Heinisch/G. Pürstinger (Innsbruck)],
Belgium [A. Vlietinck (Antwerp)], Belarussia [I.A. Mikhailopulo
(Minsk)], Canada [V.S. Gupta (Saskatoon), J.R. Dimmock (Sas-
katoon), G. Henson, M.J. Abrams and G. Bridger (AnorMed at
Langley, British Columbia), L.I. Wiebe and E.E. Knaus (Edmon-
ton)], Croatia [M. Mintas and S. Raic-Malic (Zagreb), L.J. Tusek-
Bozic (Zagreb)], Egypt [E.-S. El-Ashry (Alexandria)], France [A.
Gueifﬁer (Tours), G. Guillerm (Reims), S. Kirkiacharian (Paris-
Sud), B. Meunier (Toulouse), M. Reboud-Ravaux (Paris), J.-P.
Roque (Montpellier)], Germany [W. Pﬂeiderer (Konstanz),
F. Seela/H. Rosemeyer (Osnabrück), P. Wutzler (Erfurt)], Greece
[N. Kolocouris (Athens), D. Papaioannou/G. Balayiannis (Patras)],
Hungary [L. Ötvös/G. Sagi (Budapest), F. Sztaricskai (Debrecen)],
India [S.S. Karki (Bangalore), S.B. Katti (Lucknow), T. Pathak
(Pune), A.K. Prasad (Delhi), K.N. Singh (Varanasi)], Ireland
[M. Lewis (Trinity College, Dublin)], Italy [A. Chimirri (Messina),
S. Manfredini/P. Baraldi (Ferrara), G. Natile (Bari), M. Roberti
(Bologna), G. Romeo/U. Chiacchio (Messina)], Japan [M. Baba
(Kagoshima), T. Maruyama (Tokushima), A. Matsuda (Sapporo),
H. Tanaka (Tokyo), M. Ubasawa (Yokohama)], Korea [Chong-
Kyo Lee (Taejon), Jong Chan Son (Taejon)], Mauritius
[S. Jhaumeer-Laulloo/S.R. Ramadas (Reduit)], Morocco [H.B.
Lazrek (Marrakech)], The Netherlands [A.D.M.E. Osterhaus
(Rotterdam), H. Timmerman (Amsterdam)], Norway [M.L. Sand-
vold/F. Myhren (Porsgrunn)], People's Republic of China
[Xinyong Liu (Shandong University, Jinan), Fen-Er Chen (Fudan
University, Shangai)], Poland [J. Boryski/B. Golankiewicz (Poz-
nan), T. Kulikowski/D. Shugar (Warsaw), W.J. Stec (Lodz)],
Russia [A.A. Ozerov/M.S. Novikoff (Volgograd), M. Preobraz-
henskaya (Moscow)], Spain [M.-J. Camarasa (Madrid), F. Fernan-
dez-Gonzalez (Santiago de Compostela), M. Nogueras (Jaén), S.
Vega (Madrid)], Switzerland [J.M.J. Tronchet (Geneva)], Taiwan
(Jih-Rhu (Ruben) Hwu], Turkey [I. Küçükgüzel (Istanbul)], United
Kingdom [S.J. Archibald (Hull), C. McGuigan (Cardiff),avir and cobicistat (Tybosts).
Table 1 Listing of the most productive science authors of 1991 (Science 1993; 259:180).
Scientiﬁc papers: top producers of 1991
Rank Researcher Papers Authors per paper
1. Thomas E. Starzl, transplant surgery 155 7.8
U. Pittsburgh
2. Yury T. Struchkov, chemistry/crystallography 83 6.0
Inst. Organoelemental Compounds, Moscow
3. K. Ploog, condensed-matter physics 81 5.0
Max Planck Institut für Festkörperforschung, Stuttgart, Germany
4. Eric De Clercq, virology 80 6.0
Catholic University of Louvain, Belgium
5. John J. Fung, transplant surgery 72 8.1
U. Pittsburgh
6. Pierre Braquet, immunology/pharmacology 61 5.4
Institute Henri Beaufour, Le Plessis Robinson, France
7. Virgil Percec, organic and polymer chemistry 56 2.7
Case Western Reserve University, Cleveland
8. Allan H. White, physical and inorganic chemistry 51 4.9
U. Western Australia, Nedlands
Stephen J. Pearton, condensed-matter physics 51 5.2
AT&T Bell Labs, Murray Hill, New Jersey
9. Hans Georg von Schnering, chemistry/crystallography 50 4.7
Max Planck Institut für Festkörperforschung
Carlo A. Maggi, pharmacology 50 4.8
A. Menarini Pharmaceuticals, Florence, Italy
Genrikh A. Tolstikov, chemistry/crystallography 50 5.3
Inst. Chemistry, Academy of Sciences, Ufa, Russia
An Odyssey in antiviral drug development 533P.J. Sadler (Warwick)] and the United States of America
[R.T. Borchardt (Lawrence, Kansas), M. Cushman (Purdue Uni-
versity, West Lafayette, Indiana), M.K. Lakshman (New York),
V. Marquez (Bethesda), M.J. Miller (Notre Dame, Indiana), V.
Nair (Athens, Georgia), M.J. Robins (Provo, Utah), S.W. Schneller
(Auburn, Alabama), C.E. Stephens (Augusta, Georgia), S.F. Wnuk
(Miami) and P.F. Torrence (Flagstaff, Arizona)]. I look back at
these and many other collaborations with utmost nostalgic feel-
ings, because once upon a time they launched high expectations at
both sides. Most of these collaborations died quietly because of the
protagonists disappeared or retired (like myself), but for those that
still lasted as of today, I will keep cherishing. Both those that are
gone and those that are still remaining testify as to the paradigm I
have always defended as emblematic for the triumph of science,
the innate link between chemistry and medicine.2.9. Writers’ cramp
In 1993 I featured in the issue Vol. 259 (January 1993) of Science
under the editorials on page 180 the listing of the most productive
(proliﬁc) science authors of 1991 (Table 1). I ranked No. 4 world-
wide after No. 1 Thomas Starzl (from Pittsburgh), a transplant
surgeon, No. 2 Yury T. Struchkov, and No. 3. K. Ploog, with some
80 publications per year. Starzl had 155 publications for 1991. I
wondered how he did achieve this quasi Herculean task. Little did I
know that in January 2005, I would meet him in person at a rather
small meeting of the Philosophical Society in Philadelphia, in honor
of Maurice Hilleman, a few months before Maurice passed away
from pancreatic cancer. At the speakers' party the night before the
meeting, I was sitting next to Starzl, but I don't remember we talked
about publications. This is the only time I have ever met Starzl. The
meeting honored Maurice Hilleman, who for all these years hadstayed my hero (also present at the meeting were Tony Fauci, Bob
Gallo, Stanley Plotkin, Hilary Koprowski, Roy Vagelos, and from
the European side only Ehrling Norrby, Britta Wahren, and myself).
It was at this meeting that Roy Vagelos epitaphed that “M. Hilleman
was a bastard from the outside, but from the inside, he was still a
bastard”. Bob Gallo had hoped to honor Hilleman again in April
2006, tentatively in Taormina (Sicily), but Maurice's death on 11
April 2005 trespassed these plans. My publication record leveled off
at 100 per year, before it started to sharply decline with my
retirement in 2006. University rules in Belgium dictate that from the
age of 65, any professor is discharged from all his functions:
administration, teaching and research. While I readily accepted this
rule for the administrative duties, I found it totally unacceptable for
research and teaching. I bitterly resented and objected to this
obligatory retirement, but even almost 10 years after the verdict, I
still feel it hard to accept and consider the obligatory abdication of
my research and teaching duties as unjustiﬁed, penalizing and
discriminatory. University authorities (rectors and the like) consis-
tently admitted it was a great pity that I could not continue my job,
but nobody undertook any action, or (to use soccer terms) passed an
assist to any other responsible (and responsive) person to overrule
the ordeal. The sole attempt to try to break this rule came from
Antonín Holý. In a handwritten letter of 2 pages in 2004, which I
have kept as a relic. He pointed out the possibility of leaving
Leuven and join him at the IOCB in Prague. Although this transition
was never formalized, it made me to come over to the Czech
Republic more often. I became an honorary doctor, thanks to Holý,
at Charles University in Prague, and after Holý had brought me into
contact with his good friend, Libor Grubhoffer in České Budějovice,
both Holý and I were together promoted to honorary doctors in
České Budějovice in 2009, and from 2007 till today I am still
teaching the course of “Chemistry at the Service of Medicine” at
Jihočeská University in České Budějovice, and I must confess I
Erik De Clercq534immensely appreciate this opportunity to continue teaching, which I
hope to continue as long as my capabilities permit to do so.
2.10. Teaching
In 1965 an afﬁliated campus to Leuven, the KULAK, was started
with some faculties in the humanities (linguistics, law, philoso-
phy). In 1971, the Faculty of Medicine was added (this was just
after my return from Stanford), and Prof. P. De Somer, already
endowed with the function of rector, invited me to teach
biochemistry in the 2nd and 3rd year of medicine, together with
a colleague of mine, Marcel Joniau. Joniau was a real biochemist,
who was interested in medicine, whereas I was a medical doctor
interested in biochemistry. It was hard to predict that I would
continue teaching in Kortrijk at the KULAK for 37 years, from
1972 to 2009 (Joniau would stop teaching when he had to retire in
2004). Together we formed an ideal couple, teaching and
examining the students for their insights in (bio)chemistry
especially as related to medicine. In the more than 30 years when
we were teaching the course, I don't remember any quarrel or
dispute. As the years passed by, we felt each other's needs,
capacities and attitudes even better, and when Marcel Joniau had
to abandon his teaching, I felt like I had lost my “compagnon de
route in teaching”. It was the prelude of my own farewell to the
teaching in Kortrijk. At the KULAK I met wonderful colleagues,
invariably from other faculties (Mgr. G. Maertens, Prof. Baron
Louis Suetens, Louis Vos, Jean Goossens, Christophe Waelkens,
Madeleine Sergeant, Odon Leys, Luc Draye, Michel Cloet, Jos
Monballyu, etc. From Mgr. Maertens I remember an anecdote
when he had observed that P.C. Paardekoper when sunbathing
with his torso naked, that this was not decent to appear like this, in
front of the students, adding to his statement that his remarks were
not from ethical but esthetical nature (Mgr. Maertens taught the
course of ethics to the medical students). Yet, the KULAK did not
seem to recognize or appreciate my 37 year service of teaching
(including the examinations of circa 5000 students). When I
stopped teaching in Kortrijk after 37 years, there was not even any
token of recognition, let stand, gratitude. I left Kortrijk in 2009 the
same way as I had entered it in 1972, unnoticed.
Conclusion: retrospectives
Over the whole period of my academic career, I have always
divided my time for research, teaching and organizational activ-
ities. Highlights in research were the discovery (in 1978) of BVDU
as a highly selective anti-HSV-1 and anti-VZV agent, that was
eventually approved for the systemic (oral) treatment of herpes
zoster. In the early 1980s followed the acyclovir aminoacyl esters,
the prototype of which, the valine ester of acyclovir, would
succeed acyclovir for the treatment of HSV and VZV infections.
In the wake of the AIDS epidemic, followed in 1986 the discovery
of d4T, for which our laboratory got the scientiﬁc credit, but not
the ﬁnancial one. The year 1986 also marked the birth of the
acyclic nucleoside phosphonates (ANPs) with (S)-HPMPA and
PMEA (adefovir), which in 1987 would be followed by (S)-
HPMPC (cidofovir) and in 1993 by (R)-PMPA (tenofovir). The
birth of the NNRTIs dated back from the late 1980s with the
discovery of HEPT (in 1987) and TIBO (in 1988).
This research found its “raison d'être” in the contacts, apprecia-
tion and encouragements I continuously had from the collabora-
tions with at their height about 200 chemists worldwide, foremostamong them are, Antonín Holý (Prague) and John C. Martin
(Gilead Sciences). The collaboration with Holý started in 1976
(and ended with his death in 2012), that with Martin started in
1986 (and still continues). My research duties never hampered my
teaching (mainly biochemistry and virology) which I had started in
1972 at the KULAK in Kortrijk, where I continued teaching till
2009. For the courses of virology (which I had to relinquish in
2006) I was also appointed from the early 1990s in Leuven. Both
in Leuven and Kortrijk my teaching only involved medical
students (Medical School). Teaching was fun, and so were the
three NATO ASIs I ever organized, with R.T. Walker as co-
director, in Sogesta (Italy) in 1979 (which was also co-organized
by F. Eckstein), Les Arcs (France) in 1983 and Il Ciocco (Italy) in
1987. From these NATO meetings emanated from 1988, the ICAR
meetings, which have continued ever since on an annual basis, and
of which the 28th was held on 11–15 May 2015 in Rome (Italy).
My comments
Highlights in antiviral drug research are serendipity, collegiality,
collaborative ties and making competitors happy. Acyclovir, the
gold standard among the antiviral drugs, was discovered by
chance, or serendipitously. It was originally intended as an
inhibitor of adenosine deaminase, to potentiate the antiviral
activity of a known antiviral compound, vidarabine. BVDU
(brivudin) was also discovered serendipitously, when found active
against HSV-1, simply because HSV-1 together with vaccinia
virus was part of our antiviral screening assay. BVDU would later
be commercialized for the treatment of VZV infections. The
discovery of d4T should be viewed as an example of collegiality
or friendship among colleagues which should prevail over the
millions of dollars that could be generated. The NATO/FEBS
meetings that I organized fostered collaborative ties over the whole
world (US, West and East Europe, Japan and Australia), which
through the research results they generated, proved beneﬁcial to
mankind, and, as I competed (and lost) 5 times when competing
for the Francqui Prize (sometimes called the Belgian Nobel Prize)
I made 5 competitors happy, which should be viewed as a
consolation for those who participated (and lost) in the contest.III. From 2006 to 2015
In 2006 I was obliged to retire from all duties, administrative,
educational (teaching) and scientiﬁc (research). Although the
teaching at my own university was drastically reduced in 2006
and ﬁnally stopped in 2009, my love for teaching was better
appreciated in the Czech Republic where from 2007 till today I
was given the opportunity to continue teaching my favored
course “Chemistry at the service of Medicine” in Ceské
Budějovice, in a program co-sponsored by Jihočeská Univer-
sity and Kepler University in Linz (Austria). Meanwhile,
Truvadas was licensed (on 16 July 2012) for the prophylaxis
of HIV infections, the ﬁrst anti-HIV drug approved by the US
FDA for this purpose. The successor of BVDU, the valine ester
of Cf1743 (FV-100) is still under clinical development for the
treatment of VZV infections, and AMD3100 that was originally
discovered as an anti-HIV agent is now on the market (as
Mozobils) for the mobilization of (hematopoietic) stem cells.
TAF is scheduled to replace TDF in future tenofovir-based
drug combinations such as Stribilds. Holý's legacy yielded
a number of original compounds such as 1-(S)-[3-hydroxy-
An Odyssey in antiviral drug development 5352-(phosphonomethoxy)propyl]-5-azacytosine (HPMP-5-azaC),
and various 6-(3-hydroxy-2-(phosphonylmethoxy)propoxy)-
(HPMPO-), 6-(2-(phosphonylmethoxy)ethoxy)- (PMEO-) and
6-(2-(phosphonylmethoxy)propoxy)-2,4-diaminopyrimidine
(PMPO-DAPy) derivatives, for which the future clinical
development looks uncertain. At the international pharma-
ceutical drug scene, much interest has shifted from HIV to
HCV, where the prospects for a real cure have become
realistic with the advent of sofosbuvir (Sovaldis) and
ledipasvir, and the combination thereof (Harvonis).3.1. 2006, the hoax
I knew beforehand that the year 2006 would be disastrous, because
I would turn 65 years old on 28 March 2006, and this should be
the inevitable end of my active career. A committee, existing of
the Vice-Rector, Mark Waer, the General Commissioner, Koen-
raad Debackere, the Dean of the Medical Faculty, Bernard
Himpens, and a certain Bamelis from the Board of the KU Leuven
Directors, was installed, in my honor, to streamline the transition
from the active professorship to the retired emeritus state. Not all
retiring professors get such distinguished funeral. This is reserved
for the happy few. It did not prevent the then acting Rector, Mark
Vervenne, from sending me a formal letter, separately from the
Committee's decision that as of October ﬁrst, 2006, I would be
relieved from all my functions, administration, teaching and
research. No alternatives were offered, as if it could be presumed
that retirement would be quickly followed, possibly by a causal
relationship, by death. In any case the Committee had by
November 2006 prepared a text, written by Bernard Himpens,
where they complimented me, still alive, for the nice legacy I had
left. They must have referred to my exemplary teaching (up to 11
hours per week), publication record (then exceeding 2000, now
more than 2,500, publications in peer-reviewed journals resulting
in ten thousands of citations), and about ten of my pupils who
succeeded me as professors. As Prof. Marcel Janssens (Linguis-
tics), who was succeeded by six professors, once said in his
farewell speech, “I must have been a very cheap employee at the
University, as they now have to pay six times more for the same
job done”. The money I generated for the university, in terms of
royalties, became redeemed only from 2008 onwards, and this
brought the KU Leuven in the top ten ranking of the universities
over the world. The management of the university has been well
aware of these royalties (received from Gilead Sciences), but the
origin of the money remained a rather well-kept secret, as if it had
fallen, like manna, from Heaven (at a Catholic university, miracles
may have been considered likely to happen!). Some of my good
friends (as Prof. Frank Seela from Osnabrück, now at Münster, in
Germany) had warned me that, according to his own experience, I
had not to expect much clemency or gratitude from the university.
At least I could keep my parking space in front of the institute's
entrance which appeared very handy now that my walking abilities
have become problematic and my seat at the secretary's desk
which allows me to sit down, instead of standing up, when going
through my correspondence and reviewing my publications at the
service of the university.
3.2. Honorary doctorates
My ﬁrst honorary doctor's degree in 1997 was from the University
of Ghent. The eloge (“laudatio”) was pronounced by Prof. DenisDe Keukeleire, worldwide known as beer-expert (“zytologist”),
equivalent to a wine expert (“oenologist”). Denis had once visited
the NIH library in Bethesda, and when looking for how many
times his name was cited, his eyes fell on a certain De Clercq,
whose name was listed just (or a few places) before his name.
Exploring my CV in some further detail, and after consulting Piet
Herdewijn, Denis introduced me for an honorary doctorate in
pharmacy, as it was the annual turn for this discipline. I was proud
with this honor from Ghent, as it bestowed me with the same
distinction in Ghent as my mentor, Prof. P. De Somer, once got.
That same year (1997) followed an honorary doctor's degree, again
in pharmacy in Athens, with Prof. Nicolas Kolocouris as my
promoter. Then followed in 2000, an honorary degree, again in
pharmacia, at the University of Ferrara, with Stefano Manfredini as
my promoter (and Pier Giovanni Baraldi (as co-promoter, and
promoter of Dale Boger who got at the same occasion also an
honorary doctor's degree from Ferrara). Incidentally, Copernicus
and Paracelsus are also honorary doctors from Ferrara. Then
followed in 2005, an honorary doctorate (actually professorship)
from Shandong University, Jinan (with Xinyong Liu as promoter)
From this university I got the nicest robe “toga”, all in red, and so
many gifts my host provided me with so that I had to get an
additional suitcase to take it all home. On 7 March 2007, I was
awarded a doctor's degree, this time in medicine, from Charles
University, Prague, certainly with the help of Antonín Holý. In the
spring of 2007, I also gave a course of 15 hours on antivirals at
Charles University, and in the fall of 2007 I started my teaching in
České Budějovice (I had to identify the location and exact
pronunciation of České Budějovice), where together with Antonín
Holý, I was awarded an honorary degree on 4 June 2009. Our
promoter in České Budějovice was Prof. Libor Grubhoffer. Two
additional honorary degrees would follow: in 2010 in Tours
(France) and in 2011 in Hull (United Kingdom), respectively,
with Alain Gueifﬁer and Steven Archibald as my promoters. This
would conclude my honorary doctorships. On 8 June 2013 I would
be honored by an honorary citizenship from my native town,
Hamme, which at least partially contradicts the general saying that
“one is never recognized at one's own place”. The honorary
citizenship in Hamme, which I cherish immensely, testiﬁes as to
the opposite.3.3. Tsai et al. (1995)
In 1995, I appeared on the Belgian TV (VTM) to support the
importance of lamivudine (Epivirs) from GSK, as an anti-HIV
drug, with equally remarkable activity against HBV. I told the
journalist, I was delighted to do this public relations (PR) job for
GSK, but that I would even be more delighted to do this over
again for my own product, (R)-PMPA (or tenofovir) for which I
had heard that Tsai et al.43 had found remarkable activity against
SIV (simian immunodeﬁciency virus), far superior to that of AZT
(azidothymidine). These results would be communicated in the 17
November 1995 issue of Science. I informed the Belgian TV
(VTM) that this was going to happen and told them I would not
mind to appear on TV again to talk about my own product44 that
had been licensed to Gilead for further development. At the TV
they told me that they would be most interested to interview me on
Friday, 17 November 1995, but, when I told them, this would not
work out because Fridays were reserved for my teaching at the
KULAK in Kortrijk, I had hoped they would call it off, but on the
contrary, they came over to Kortrijk to interview me, in front of
Figure 21 Protein immunoblot analysis of SIV-speciﬁc antibody
response in macaques 20 weeks post infection with SIV. Mock-treated
control macaques (n¼10) and macaques treated with PMPA (tenofo-
vir) starting at 24 h post infection (n¼5) are presented. Antibodies to
env glycoprotein gp120, gag proteins p28, p16 and p8 and vpx protein
p14 were detected in all of the control macaques. None of the
macaques treated with PMPA starting 24 h post infection showed SIV-
speciﬁc antibodies (Tsai et al.43).
Erik De Clercq536the students (who very much enjoyed such exceptional event in the
otherwise rather boring KULAK or Kortrijk environment). Hence,
my performance was put on TV (for which the Campus Rector Vic
Nachtergaele, whom I did not ask for permission, congratulated
me later wholeheartedly). The interview went very well, until the
TV reporter suddenly asked whether I had now discovered the
“morning after” pill for the treatment of AIDS. This question was
not foreseen in a life edition (prime time) on TV, so that, taken by
surprise, I must have answered, this may have been the “morning
after”, but it still was not a “pill” yet. The appearance on TV in
Kortrijk, may certainly have added to my prestige in the Texas
(Dallas) part of Belgium, but remained largely unnoticed in
Leuven. In looking back at the Tsai et al. paper43 (Fig. 21), it
indeed marked the use of the “morning pill” of (R)-PMPA, later
formulated as tenofovir disoproxil fumarate, in combination with
emtricitabine (Truvadas), which had in 2004 been commercia-
lized for the treatment of AIDS, and eight years later, on 16 July
2012, was approved by the US FDA for the prevention of AIDS.
That same day coincided with the death of Antonín Holý, co-
inventor of what I had announced on 17 November in 1995 on
television as the “morning after” pill for AIDS.
3.4. Nature reviews drug discovery/biochemical pharmacology
In 2000 I was awarded the Otto Krayer Award from ASPET
(American Society of Pharmacology and ExperimentalTherapeutics). The award was handed over by Sam Enna in
Orlando (at the end of March) and a few days later I gave the
commemorative lecture later published in the Journal of Pharma-
cology and Experimental Therapeutics45. Present in the audience
was a certain Mr. Smith, Editor of a new journal (Nature Reviews
Drug Discovery, NRDD) who invited me to write a review article
for NRDD, which was published in 200246. In 2003 I published a
perspective article on AMD3100 (see section on AMD3100) in
NRDD47, which summarized the saga on the discovery of
AMD3100 from its early days when it was recognized as an
anti-HIV agent until its recognition as an hematopoietic stem cell
mobilizer. Additional, more recent review articles would follow on
the stem cell mobilization of AMD3100 after it had been marketed
as Mozobil48,49. In 2004, I wrote a review article for Nature
Reviews Microbiology50, and in 2005, I returned to NRDD51 with
a review article on the acyclic nucleoside phosphonates with
Antonín Holý as co-author: it covered our collaboration over a 20-
year period, from 1985 till 2005. Although I was not actively
involved in experimental work with inﬂuenza or antivirals against
inﬂuenza, I wrote purely from scientiﬁc interest a review article on
inﬂuenza in NRDD52, simultaneously with a more chemically
oriented paper that I co-authored with Irène Lagoja in Medicinal
Research Reviews53. In 2007 I would write my last paper for
NRDD54. It was worth a double paper, as it covered both HIV and
HCV, highlighting the similarities (and dissimilarities) between
anti-HIV and anti-HCV agents and their mechanism(s) of action.
Eventually I would start writing a paper on cellular targets for
antivirals, intended for publication in NRDD, but the paper was
never completed, and has thus remained unpublished. Instead I
kept writing commentaries for Biochemical Pharmacology, on a
wide variety of antiviral compounds, strategies, and perspec-
tives55–60, most recently focused on Ebola virus (therapeutic
strategies)61.3.5. The successor of BVDU
BVDU appeared to be the most potent anti-VZV agent, ever
described until 2000, far exceeding the acyclic nucleoside analo-
gues acyclovir (valacyclovir), ganciclovir and penciclovir (famci-
clovir) in anti-VZV potency. Then, in 2000, McGuigan et al.
described a new 2′-deoxynucleoside analogue, bicyclic nucleoside
analogue (BCNA), actually a bicyclic furo [2,3-d]pyrimidine
derivative (Cf 1743, Cf standing for Cardiff)62, which was still
about 10-fold more potent than BVDU. This type of molecule
contains a highly apolar tail which must function as a ligand to ﬁt
snugly into a cleft of the VZV thymidine kinase (TK). Although
the BCNA is structurally unrelated to the bicyclam AMD3100, it
is curious to note that for both sorts of compounds the replacement
of an aliphatic by an aromatic bridge in the bicyclams, when
moving from JM2763 to JM310063,64, and the introduction of an
aromatic phenyl moiety into an entirely aliphatic side chain of the
BCNA62,65, led to a quantum jump in potency against either HIV
or VZV, respectively. Whereas BVDU was active against HSV-1,
VZV and some herpesviruses of veterinary importance, Cf 1743
was uniquely active against VZV. The exquisite potency of Cf
1743 against VZV has been convincingly demonstrated by Andrei
et al.66 It clearly depends on a speciﬁc interaction of the compound
with the viral TK. This interaction is necessary but not sufﬁcient to
explain the anti-VZV activity of the compound: for example, it has
not been resolved whether the compound has to be phosphorylated
to either the mono-, di- or triphosphate to be antivirally active. In
Figure 22 Structures of Cf1743 and FV-100.
Figure 23 Structure of AMD3100.
Figure 24 WBC ratio versus time compared to AMD3100 concen-
tration versus time following single-dose intravenous AMD3100
administration (Hendrix et al.72).
An Odyssey in antiviral drug development 537analogy with the conversion of acyclovir to valacyclovir, Cf 1743
(Fig. 22) was also converted to its 5′-valine ester (termed FV-100,
FV standing for Fermavir)67. Migliore68 called FV-100 the most
potent and selective anti-VZV agent reported to date. The
compound is not only very active, it can also be guaranteed to
be safe, and unlike 1-β-D-Arabinofuranosyl-(E)-5-(2-bromovinyl)
uracil (BVaraU), another potent anti-VZV compound, Cf 1743 (or
FV-100) is devoid of any potential interaction with the catabolism
of the anticancer drug 5-ﬂuorouracil. Phase II clinical trials with
FV-100 in the treatment of herpes zoster look very encouraging69.
In the unique speciﬁcity of FV-100 against VZV lie both its
strength and weakness, the latter being due to its limited
therapeutic activity spectrum (VZV only).3.6. AMD3100-Mozobil™
AMD3100 started as an impurity present in a preparation
(JM1600) sent from Johnson Matthey (JM) to be checked for its
anti-HIV activity at the Rega Institute. This sort of compounds, the
bicyclams, had never been accredited with any antiviral properties,
let stand anti-HIV activity, so there were no precedents. Its mode
of action was attributed to a possible interference with HIV entry
into the cells (then interpreted as “uncoating”). The paper was
published in the PNAS in 199263 sponsored by the Nobel Prize
winner, Max Perutz. Starting from JM1600 as the model com-
pound, JM2763 was described as an anti-HIV agent63 and in
199464 we came up with an even more potent anti-HIV agent,
JM3100, having anti-HIV activity in the nanomolar concentration
range, the name was changed to AMD3100 (Fig. 23) when
AnorMed was created as a spin off from JM. In AMD3100 the
aliphatic bridge tethering the cyclam moieties is replaced by an
aromatic (i.e., phenylene bis-methyl) bridge. The activity andspeciﬁcity of AMD3100 was such that it surpassed all known anti-
HIV agents in both potency and selectivity. Together with my JM
colleagues (Don Picker, Mike Abrams, Geoff Henson and Gary
Bridger, whom I unrespectfully sometimes referred to as the four
“Daltons”), I went on a road tour, in an attempt to get
pharmaceutical companies (JM being a chemical company) inter-
ested. We visited about 15 companies, to whom I could tell the
story, and, ﬁnally, Sandoz (Basel) took it over. Sandoz (with Rolf
Datema) actively pursued the compound until, on a blue Monday
sometime in November 1998, Sandoz merged with Ciba-Geigy to
become Novartis, and consequently they dropped their entire anti-
HIV program encompassing not only JM3100 (AMD3100), but
also a cyclosporin derivative and a protease inhibitor, which if
combined may have allowed Sandoz (or Novartis) at the end of the
1990s to become the leader in the ﬁeld. Meanwhile, in 1997, we
had discovered the reason for the anti-HIV activity of AMD3100,
that is a speciﬁc interaction with CXCR4, the co-receptor for
T-lymphotropic strains of HIV to enter the cells (the co-receptor
for the M (macrophage) tropic strains being CCR5)70,71. Under the
auspices of AnorMed, they started at Johns Hopkins the ﬁrst
clinical trials, where Craig Hendrix and his colleagues72 found that
AMD3100 at 8–10 hours upon intravenous (or subcutaneous)
injection caused a remarkable increase in the white blood cell
(WBC) counts (Fig. 24), which was just the opposite of what to be
expected from cytotoxic compounds. These white blood cells, at
Figure 25 Structure of tenofovir alafenamide (TAF).
Erik De Clercq538closer inspection, appeared to carry the CD34 marker, which
identiﬁed them as belonging to the hematopoietic stem cell (HSC)
type49. AMD3100 thus qualiﬁed as a stem cell mobilizer, and
while it was never commercialized as an anti-HIV drug for which
it was originally intended, it was ﬁnally commercialized as a stem
cell mobilizer (Mozobil™) by Genzyme after they had taken over
AnorMed (Genzyme is now part of an even larger company,
Sanoﬁ). Mozobil is used for autologous transplantation of
hematopoietic stem cells in patients with non-Hodgkin's lym-
phoma (NHL) or multiple myeloma (MM). It should be further
explored for its stem cell mobilization in other pathophysiologic
conditions, including malignant and rheumatic diseases, and tissue
regeneration.
3.7. Paul Janssen and John C. Martin united: Complera/
Eviplera
The year 1986 was crucial in our search for anti-HIV agents. This
year we described (with Antonín Holý) the broad-spectrum anti-
DNA virus activity of (S)-HPMPA as the prototype of the ANPs73.
On 6 of November 1986 I visited Paul Janssen, with whom I spent
about 8 hours together (including lunch and dinner) in Beerse. We
discussed the feasibility to join our forces to discover the “ideal”
(miraculous) drug for the treatment of AIDS, which had now
become a full-ﬂedged globally feared epidemic, for which at the
end of 1987 we would discover HEPT, and in 1988, the TIBO
compounds. In this period I often traveled to Bristol-Myers at
Wallingford, where my host was John C. Martin. At one of the
diners preceding my formal lecture the next morning John would
interrogate me (as he always did). One of his penetrating questions
was which compound I would prefer for the treatment of AIDS, an
ANP (the ANP he meant was PMEA) or TIBO. I told him he
probably needed both, to hit vigorously with an ANP (running the
risk for toxicity without much risk for resistance development),
and smoothly (elegantly) with TIBO (no toxicity but risk for
resistance). This distinction was perhaps not entirely correct, but
emblematically it predicted the combination that more than twenty
years later became one of the most successful regimes for the
treatment of AIDS, the combination of TDF as an ANP derivative
and rilpivirine as a TIBO derivative (now generally referred to as a
NNRTI). This combination has been dubbed Compleras (in the
US) and Evipleras (in the EU)56. It contains tenofovir, which we
described as (R)-PMPA44 and rilpivirine, which Dr. Paul con-
sidered his “miraculous” (or at least the ideal) drug for the
treatment of AIDS74.
3.8. TAF
In the original agreement signed by the inventors, Antonín Holý
and myself, and Bristol-Myers (the agreement was later taken over
by Gilead Sciences), it was agreed that to compensate for the
rather symbolic downpayment fee received for our invention, we
should receive royalties on the prodrugs that would ever be
synthesized from the original compounds such as tenofovir. The
original patent on tenofovir [(R)-PMPA] dates from 1992 (pub-
lished in 199344), but the patent on its prodrug TDF is going back
till 199775,76, so that if the 20-year protection time is respected, the
protection of TDF is expiring in 2017. However, in the meantime,
a new prodrug of tenofovir, GS-7340 or 9-[(R)-2-[[[[(S)-1-(iso-
propoxycarbonyl)ethyl]amino]phenoxy-phosphinyl]methoxy]pro-
pyl]adenine (Fig. 25), dubbed TAF, has been synthesized77,78, theunique propensity of GS-7340 to be preferentially taken up by the
lymphatic tissue was published in 2005 by Lee et al79. (patented in
2004 so that it remains protected until 2024). In HIV-1-infected
patients, 10-day monotherapy with 25 mg TAF demonstrated
superior efﬁcacy, due to its higher uptake by the lymphoid cells,
than TDF administered at 300 mg80. GS-7340 effected high and
persistent levels of (R)-PMPApp in peripheral blood mononuclear
cells following oral administration of TAF81. It is to be anticipated
that in the future TDF may be replaced by TAF in all combinations
containing TDF (i.e., Truvadas, Atriplas, Compleras/Evipleras,
Stribilds), and that other combinations containing TAF (i.e., with
darunavir) may be launched.3.9. Antonín Holý legacy
While an impressive number of Holý's compounds reached the
market, an even more impressive number of valuable (potential)
candidate drugs did not, the ﬁrst being (S)-HPMPA73 but also its
diamino counterpart (S)-HPMPDAP82. Neither did the diamino
counterpart of adefovir (PMEA), 9-(2-phosphonylmethoxyethyl)-
2,6-diaminopurine (PMEDAP). This must have something to do
with the prejudice that nature did not select 2,6-diaminopurine as a
natural base in its “repertoire” of purines (adenine, guanine and
hypoxanthine) and pyrimidines (cytosine, thymine and uracil).
Additional considerations may be the fact that no antivirals are
known to be built upon a 2,6-diaminopurine as heterocycle, that
2,6-diaminopurine skeleton may be quickly metabolized to a
guanine moiety, and if it were to be incorporated as such into
DNA, it may lead to (transition) mutations. Of the guanine
derivatives, PMEG [9-(2-phosphonomethoxyethyl)guanine] has
been known since 198783, but considered to be too (cyto)toxic
to be further pursued for its antiviral potential. Instead, it has been
further explored for its antitumor potential as its prodrug cPrPME-
DAP [9-(2-phosphonomethoxyethyl)-N6-cyclopropyl-2,6-diamino-
purine], from which two proprodrugs were prepared: GS-9191
(Fig. 26), which is further explored by Graceway Pharmaceuticals
(Bristol, TN) for the topical treatment of genital warts (in humans);
and GS-9219 (Fig. 27), which is evaluated by Vet DC (Fort
Collins, CO) for the intravenous treatment of NHL in dogs. A
series of compounds for which Antonín Holý had high hopes are
the so-called O-DAPy derivatives (R)-HPMPO-DAPy, PMEO-
DAPy and (R)-PMPO-DAPy (DAPy standing for 2,4-diaminopyr-
imidine, the oxygen linking the C-6 of the pyrimidine with the
acyclic side chain). The prototype of these compounds had been
described by Holý in 200284. Although the 6-[2-(phosphono-
methoxy)alkoxy]-2,4-diaminopyrimidines are pyrimidine derivatives
An Odyssey in antiviral drug development 539(Fig. 28), they act as purine nucleotide mimetics. Their spectrum and
mode of action, and especially their therapeutic potential, remain
largely unexplored85. Following a tradition initiated at the IOCB in
the 1960s by Dr. Holý's boss, Dr. František Šorm86, Holý, in the last
years of his life, turned his attention to replacing the pyrimidine
moiety of (S)-HPMPC by a triazine moiety, 5-azacytosine, thusFigure 27 Structure of GS-9219.
Figure 28 Structures
Figure 26 Structure of GS-9191.synthesizing (S)-HPMP-5-azaC, its cyclic derivative, (S)-cHPMP-5-
azaC and several alkoxyalkyl ester prodrugs thereof (Fig. 29)87. The
5-azacytosine counterpart of (S)-HPMPC (and its prodrugs) may be
worth further evaluating now that the intellectual property protection
period of (S)-HPMPC has expired.3.10. Sofosbuvir
HCV is fundamentally different from HIV and HBV: HIV is a
retrovirus that transcribes its RNA by the virus-associated reverse
transcriptase (RT) into DNA which is then integrated by the virus-
associated integrase into the chromosomal DNA. HBV is an
hepadnavirus, a DNA virus, which can persist in the HBV-infected
cell as cccDNA (ccc¼covalently closed circular). HCV, on the
other hand, is an RNA virus (i.e., hepacivirus, belonging to the
ﬂaviviridae). Like RNA viruses in general it does not replicate
through a DNA intermediate. It can thus be eradicated, and this is
the current aim of the treatment, that is to eliminate it as soon as
possible. For the last decade, standard treatment of HCV infections
existed of pegylated (PEG) interferon combined with ribavirin.
This standard of care (SOC) will soon belong (or already belongs)
to the past. There are now plenty of direct-acting antivirals
(DAAs) at hand, which inhibit the replication of HCV: they are
mainly targeted at speciﬁc viral proteins (NS3/4A protease, NS5A
protein, NS5B polymerase (nucleoside (N)-type of inhibitors),
NS5B polymerase (non-nucleoside (NN) type of inhibitors)).
Some (i.e. cyclosporins) are targeted at a cellular target (i.e.
cyclophilin). Personally I have been involved with some of the NN
type of NS5B polymerase inhibitors (i.e. tegobuvir (GS-9190)) and
cyclosporin inhibitors of both HIV and HCV. The most promising
DAA, however, is sofosbuvir (Sovaldis) (Fig. 30). It is a highly
decorated uracil derivative with high potency against all HCV
genotypes (1–6), devoid of any signiﬁcant side effects, and not
leading to resistance development within the proposed treatment
duration time of 12 weeks60,88. Sofosbuvir will likely become the
cornerstone for the treatment of hepatitis C, offering the tantalizing
perspective that it will be the ﬁrst antiviral drug ever shown to be
effective in eliminating (or curing) an established virus infection.
To this end, sofosbuvir may be combined with one or more other
DAAs, such as ledipasvir, a NS5A inhibitor. This combination
strategy has already been shown to achieve a sustained viral
response (synonymous for cure) after a treatment period of 8–12
weeks. In the future, treatment of hepatitis C may even be further
shortened with sofosbuvir used in the appropriate combination
with other DAAs (such as ledipasvir).of the O-DAPys.
Figure 29 Structures of (S)-HPMP-5-azaC and derivatives thereof.
Figure 30 Structure of sofosbuvir (Sovaldis).
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With BVDU being generic, standing out as the optimal choice for
the treatment of VZV infections (shingles, herpes zoster) is FV-
100, the 5′-valine ester of Cf1743. Although FV-100 is the most
potent and selective anti-VZV agent ever reported, it is question-
able whether it would ever be developed and commercialized
because of its limited usefulness (VZV only).
Mozobil, originally discovered as an anti-HIV agent, has
through a highly convoluted development pathway been even-
tually marketed as a stem cell mobilizer. Its future lies in various
aspects of stem cell mobilization including tissue regeneration.
With TDF turning generic in 2017, its successor will be TAF,
which is about 10–30 times more potent than TDF and preferen-
tially be taken up by the lymphatic tissue. In future combinations
based on TDF, TAF will take over its place, i.e., in combination
with emtricitabine and rilpivirine, or in combination with emtri-
citabine and elvitegravir and cobicistat, or in combination with
protease inhibitors such as darunavir. Except for tenofovir (TAF),
it does not seem obvious that other compounds from Holý's
legacy, i.e., the so-called O-DAPy derivatives (i.e., (R)-HPMPO-
DAPy, PMEO-DAPy or (R)-PMPO-DAPy), or the 5-azaC deriva-
tives, would be developed or marketed for human use.
While for HIV, the prospects for a cure have continued to
remain enigmatic, there is more hope for a cure for HBV. For
HCV, however, success for a cure with sofosbuvir (Sovaldis) with
or without other DAAs such as ledipasvir, can be guaranteed for
circa 90% of the patients within a time period of 12 weeks. In the
future, this time period may be shortened to 8 or even 6 weeks,
and be guaranteed for all patients, irrespective of their (1–6)
genotype.My comments
There are a few messages I want to convey: (i), teaching and research
are complementary in that they cross-fertilize each other: teaching
helps resolving problems that could help in successfully planning
research, and research should help formulating how to teach; (ii)
collaboration between three disciplines (chemistry, biology, industrial
exploitation) is mandatory in drug development: the chemist should
contact the biologist to ﬁnd out what is important for a new chemical
entity; and for both, the contact with industry should be essential on
how to best commercialize their ﬁnding in the beneﬁt of mankind. My
personal story on the “morning after pill”, ﬁrst announced on
television in November 1995, and culminating on 16 July 2012 with
the approval of Truvadas for the prevention of HIV infections,
reﬂects on the importance of perseverance. Convergence of similar
principles, i.e., replacement of an aliphatic by an aromatic moiety as in
the bicyclams and BCNAs (bicyclic nucleoside analogues), respec-
tively, may lead to new leads for anti-HIV and anti-VZV activity.
And, ﬁnally, two fundamentally different new approaches, that of the
NRTIs (tenofovir) and NNRTIs (rilpivirine), may, if brought together,
yield the ideal combination for the treatment of HIV infections.References
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An Odyssey in antiviral drug development 543CommentaryLibor Grubhoffer, Ph.D., Professor and Rector (Head), University of South Bohemia, Ceske Budejovice, Czech
Republic.First I ever met the name of Dr. Erik De Clercq was as a graduate student of virology long time ago. Since 70th of the last
century he has been systematically working on research of antivirals in the Rega Institute for Biomedical Research at Catholic
University in Louvain, Belgium. He introduced modern methods and approaches of testing as well as investigating of
biochemical mechanisms of newly synthesized compounds with antiviral activity, especially those they could block genome
replication of a broad array of animal/human viruses. As a former student and later on successor of Prof. P. De Somer has laid
the foundations of rational design of drugs with antiviral activities. Despite of that Erik De Clercq does believe in serendipity
which had played such important role in his enormously successful doing in antiviral research. One of the ﬁrst result of suchserendipity was when he proved suramin as an inhibitor of reverse transcriptase. It stimulated meaningfully his interest in reverse transcriptase, and thus
when HIV as a causative agent of AIDS appeared in beginning of 80th of last century Erik De Clercq was experienced enough to make a milestone in
research of anti-HIV compounds. The third great serendipity in the scientiﬁc career the friendship with Dr. Antonín Holý, a Czech organic chemist who
linked his whole scientiﬁc career, with the Institute of Organic Chemistry and Biochemistry in Prague, and with the synthesis of nucleoside phosphonates as
nucleic acid antimetabolites. Working together for nearly 30 years they achieved such great contribution for mankind eliminating or reducing fear from some
of viral infectious diseases.Fener Chen, Ph.D., Professor, Department of Chemistry, Fudan University, Shanghai, China.Erik De Clercq was born in Belgium (1941). He received his Ph.D. from the Katholieke Universiteit Leuven in 1972. He
served as the President of the Rega Foundation, and is a member of the Belgian (Flemish) Royal Academy of Medicine and
fellow of the American Association for the Advancement of Science. He is an active Emeritus Professor of the Katholieke
Universiteit Leuven (KU. Leuven), Belgium. He is honorary doctor of the Universities of Ghent, Belgium, Athens, Greece,
Ferrara, Italy, Jinan (Shandong), China, Charles (Prague), Czech Republic, Jihoceska, Czech Republic, Tours, France and
Hull,UK. For his pioneering efforts in antiviral research, in 1996 he received the Aventis award from the American Society for
Microbiology, and in 2000 the Maisin Prize for Biomedical Sciences from the Belgian National Science Foundation. In 2008
he was elected Inventor of the Year by the European Union. Jointly with Dr. Anthony Fauci, he received the Dr. Paul Janssen
Award for Biomedical Research in 2010. His scientiﬁc interests are in the antiviral chemotherapy ﬁeld, and, in particular, the development of new antiviral
agents for various viral infections, including herpes simplex virus (HSV), varicella-zoster virus (VZV), cytomegalovirus (CMV), human immunodeﬁciency
virus (HIV), hepatitis B virus (HBV), human papilloma virus (HPV), and hepatitis C virus (HCV). He has (co)-discovered a number of antiviral drugs,
currently used in the treatment of HSV infections (valaciclovir, Valtrex, Zelitrex), VZV infections (brivudin, Zostex, Brivirac, Zerpex), CMV infections
(cidofovir, Vistide), HBV infections (adefovir dipivoxil, Hepsera), and HIV infections (AIDS) (tenofovir disoproxil fumarate, marketed as Viread, and, in
combination with emtricitabine, as Truvada, and, in combination with both emtricitabine and efavirenz, as Atripla). Viread has also been approved for the
treatment of HBV infections (chronic hepatitis B).Denis De Keukeleire, Honorary Full Professor, Ghent University, Belgium.At our ﬁrst meeting years ago on a yearly bike outing with friendly research teams, Prof. De Clercq fascinated me by his
sporting drive, as I had already learnt that he was a most outstanding medico-scientist not only in my country Belgium, but really
on a global scale. Never before, I had met a person gifted in so many ways: from sharing numerous friends at his side taking part
in social activities and being a reputed student educator, all the way to managing a top-quality laboratory that succeeded in
combining fundamental science with real applications to the beneﬁt of countless humans (“Chemistry at the Service of Medicine”).
Such comprehensive accomplishments remain the priority of only very few! Joining forces with most prominent colleagues in
academia and with visionary industry captains, Prof. De Clercq convincingly proved how chemistry, biology, and medicine could
ultimately foster successful antiviral drug development. My greatest admiration to Prof. De Clercq concentrates on his virtues ofdedication, creativity, perseverance, honesty, enthusiasm, and, ﬁnally, ambition to be the best. I am exceedingly proud to have been privileged to introduce
Prof. De Clercq for a honorary doctorate in pharmacy at Ghent University, the ﬁrst honor preceding an impressive list of recognitions and awards.
